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Background: After renal transplantation, many patients experience adverse effects from maintenance
immunosuppressive drugs. When these adverse effects occur, patient adherence with immunosuppression may be
reduced and impact allograft survival. If these adverse effects could be prospectively monitored in an objective
manner and possibly prevented, adherence to immunosuppressive regimens could be optimized and allograft
survival improved. Prospective, standardized clinical approaches to assess immunosuppressive adverse effects by
health care providers are limited. Therefore, we developed and evaluated the application, reliability and validity of a
novel adverse effects scoring system in renal transplant recipients receiving calcineurin inhibitor (cyclosporine or
tacrolimus) and mycophenolic acid based immunosuppressive therapy.
Methods: The scoring system included 18 non-renal adverse effects organized into gastrointestinal, central nervous
system and aesthetic domains developed by a multidisciplinary physician group. Nephrologists employed this
standardized adverse effect evaluation in stable renal transplant patients using physical exam, review of systems,
recent laboratory results, and medication adherence assessment during a clinic visit. Stable renal transplant recipients
in two clinical studies were evaluated and received immunosuppressive regimens comprised of either cyclosporine or
tacrolimus with mycophenolic acid. Face, content, and construct validity were assessed to document these adverse
effect evaluations. Inter-rater reliability was determined using the Kappa statistic and intra-class correlation.
Results: A total of 58 renal transplant recipients were assessed using the adverse effects scoring system confirming
face validity. Nephrologists (subject matter experts) rated the 18 adverse effects as: 3.1 ± 0.75 out of 4 (maximum)
regarding clinical importance to verify content validity. The adverse effects scoring system distinguished 1.75-fold
increased gastrointestinal adverse effects (p = 0.008) in renal transplant recipients receiving tacrolimus and mycophenolic
acid compared to the cyclosporine regimen. This finding demonstrated construct validity. Intra-class correlation was 0.81
(95% confidence interval: 0.65-0.90) and Kappa statistic of 0.68 ± 0.25 for all 18 adverse effects and verified substantial
inter-rater reliability.
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Conclusions: This immunosuppressive adverse effects scoring system in stable renal transplant recipients was evaluated
and substantiated face, content and construct validity with inter-rater reliability. The scoring system may facilitate
prospective, standardized clinical monitoring of immunosuppressive adverse drug effects in stable renal transplant
recipients and improve medication adherence.
Keywords: Immunosuppressive agents, Adverse effects, Renal transplantation, Calcineurin inhibitors, Mycophenolic acid,
Tacrolimus, CyclosporineBackground
Renal transplantation is the preferred intervention for
patients with end-stage renal disease due to decreased
patient morbidity and mortality compared to dialysis
[1-3]. Renal transplant recipients are treated with combin-
ation immunosuppression consisting of calcineurin inhibi-
tors such as cyclosporine or tacrolimus and mycophenolic
acid to prevent allograft rejection [4]. However, these
medications are associated with significant adverse effects
which increase patient morbidity and decrease medication
adherence [4-14]. Patient non-adherence with immuno-
suppressive medications has increased as a result of mild
to moderate adverse effects which are not consistently
documented during outpatient clinic appointments. This
may impact acute rejection and long-term allograft
survival post-transplant [15-17]. Prospective clinical moni-
toring of immunosuppressive adverse effects is critical to
prevent post-transplant complications and improve
patient safety outcomes.
Routine clinical assessment of immunosuppressive
adverse effects has not included standardized, objective rat-
ing guides with quantitation of severity. Therefore, adverse
effect evaluation post-transplant is variable among clini-
cians resulting in inconsistent reporting and interventions.
Assessment is the first fundamental step in the identifica-
tion, prevention and management of adverse effects. Des-
pite routine use of prospective, standardized clinical
approaches to appraise immunosuppressive drug efficacy
by health care providers, most adverse effects are not
assessed in a systematic, objective manner. Therefore, we
developed and evaluated the application, reliability and val-
idity of a novel non-renal adverse effects assessment system
in stable renal transplant recipients receiving maintenance
immunosuppression consisting of a calcineurin inhibitor
(cyclosporine or tacrolimus) and mycophenolic acid with or
without prednisone.Methods
A novel immunosuppressive adverse effects assessment
for 18 individual adverse effects (Tables 1 and 2) were
developed by a medical sub-specialist group within the
University at Buffalo Nephrology/Transplant Program.
This adverse effect scoring system was evaluated in two
prospective studies with the enrollment of 58 stablerenal transplant recipients who participated in clinical
pharmacology studies from 2007 to 2013. Stable patients
at least 12 months post-renal transplant receiving main-
tenance immunosuppression consisting of either tacroli-
mus (Prograf) with enteric coated mycophenolate sodium
(EC-MPS; Myfortic) or cyclosporine (Neoral) with myco-
phenolate mofetil (MMF; CellCept) were enrolled. Studies
were approved by the University of Buffalo Human Sub-
jects Institutional Review Board. All patients provided in-
formed consent upon enrollment.Validity assessment
Face validity, or appearance of the scoring system to
measure the defined adverse effect parameter, was de-
veloped through nephrologist consultation with medical
sub-specialists (i.e. gastroenterologist consultation for
dyspepsia, vomiting and diarrhea) and then applied to
the target population of renal transplant recipients [18].
Content validity, or measurement of essential compo-
nents of immunosuppressive adverse effects (Tables 1
and 2) was determined by a group of nephrologists who
were subject matter experts using standard recommenda-
tions [18]. Fourteen nephrologists were invited to respond
to a survey using the standardized rating scales and docu-
ment the clinical importance of each adverse effect for as-
sessment in the renal transplant population. Nephrologists
ranked individual adverse effects for clinical importance
post-transplant using a scale of: 1 = no importance through
4 = significant importance. Descriptive statistics were deter-
mined with an a priori critical value of 3 (moderate im-
portance) to achieve content validation [18].
The adverse effects scoring system was applied to each
renal transplant recipient enrolled in two clinical studies
using similar inclusion and exclusion criteria to assess
construct validity, or the extent the scoring system mea-
sures each adverse effect described [18]. Adverse effect
ratios (gastrointestinal, central nervous system [CNS],
aesthetic and cumulative adverse effects) were compared
between renal transplant recipients stabilized on either
cyclosporine and MMF or tacrolimus and EC-MPS reg-
imens since pre-established differences in adverse effect
profiles have been reported [7,19-22]. Construct validity
was determined by analyzing adverse effect differences
between renal transplant recipients receiving these two
Table 1 Immunosuppressive adverse effects scoring system





2+: Excessive vomiting requiring symptomatic treatment
Diarrhea
0: None
1+: One loose bowel movement per day
2+: Two to five loose bowel movements per day
Dyspepsia
0: None
1+: Episode of indigestion within one hour after taking
immunosuppressive medication
2+: Indigestion for at least half the day





1+: Daily use of a histamine-2 receptor antagonist OR
a proton pump inhibitor
2+: Daily use of a histamine-2 receptor antagonist




1+: Lesion restricted to face, no specific treatment
2+: Numerous facial lesions; lesions of upper trunk
3+: Grade II and topical treatment
4+: Grade II and systemic treatment
Skin changes
0: No change
1+: No gross change but easy bruising
2+: Obvious thinning multiple or frequent ecchymoses
3+: Grade II and easy sloughing and/or striae; lacerations
Hirsutism
0: None
1+: New hair growth anywhere
2+: Marked increase in hair growth with noticeable
change in appearance
3+: Grade II and use of depilatories or shaves
Moon facies
0: No change
1+: Rounding of jaws barely detected
2+: Marked rounding with noticeable change in
appearance
3+: Grade II with plethora
Table 1 Immunosuppressive adverse effects scoring system










aThe scoring system presents a quantitative severity rating of the most
common adverse effects of immunosuppressive therapy. Each adverse effect
was assessed as a change from pre-transplant status to document that the
manifestation was attributed to immunosuppressive therapy or a change
related therapy in the post-transplant period.
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modeling.
Reliability assessment
Inter-rater reliability was evaluated in 32 stable renal
transplant recipients treated with pre-established im-
munosuppressive regimens [23]. Nephrologists separately
assessed each patient using the adverse effects scoring sys-
tem during the same clinic visit. Intra-class correlation
was generated from a pooled adverse effect score includ-
ing the 18 adverse effects. The Kappa statistic was deter-
mined for each adverse effect to document inter-rater
reliability and reported as an overall mean with standard
deviation. Intra-class correlation ≥ 0.7 and Kappa statis-
tic ≥ 0.6 were established a priori as desired endpoints
since these scores represent substantial agreement
between physician raters [23,24].
Implementation of adverse effects scoring system
Nephrologists evaluated 18 adverse effects for each renal
transplant patient during a scheduled clinic visit using ob-
jective clinical documentation including physical exam, re-
view of systems and recent laboratory results. Medication
adherence was assessed by the physician and pharmacist
through patient interviews. Evaluation of the immunosup-
pressive adverse effects using the standardized scoring sys-
tem was completed once (or twice during inter-rater
reliability phase) during a single clinic visit for each patient
in this cross-sectional study. Adverse effects were assessed
as a change from pre-transplant status in an effort to iden-
tify the post-transplant development of immunosuppressive
adverse effects. Participating nephrologists received training
prior to utilizing this adverse effect scoring system. The
scoring system focused on common non-renal adverse ef-
fects associated with immunosuppressive regimens of either
cyclosporine or tacrolimus, mycophenolic acid and low
Table 2 Immunosuppressive adverse effects scoring
system with central nervous system and miscellaneous
adverse effects
Central nervous system adverse effectsa
Tremor
0: None
1+: Noticeable movement of paper suspended
over outstretched hands with fingers spread
2+: Prominent movement of suspended paper








2+: Noticeable loss of sleep; requires
pharmacotherapy to achieve adequate sleep





1+: Complaints of muscle weakness or decreased
strength
2+: Clinically apparent weakness difficulty rising
from chair or squatting position
3+: Muscle wasting + severe limitation of exercise
capacity
Ophthalmic changes
0: No cataract formation





1+: Excitable behavior; rapid speech and activity
level
2+: Very excitable behavior, actions and speech
Depression
0: None
1+: Depressed thoughts with normal level of
activity for patient ( no antidepressants)
2+: Depressed thoughts with normal level of
activity for patient ( with antidepressants)
3+: Depressed thoughts without normal level of
activity for patient ( does not dress, poor
hygiene, etc.) and receives anti-depressants
Table 2 Immunosuppressive adverse effects scoring




Symptoms of diabetes plus casual
plasma glucose ≥200 mg/dl
OR
Fasting plasma glucose ≥126 mg/dl OR
(two of the criteria are
required)
2 hour plasma glucose ≥200 mg/dl
during an oral glucose tolerance test
OR
0: Absent Glycated Hemoglobin A1C > 7% OR
1+: Present Use of anti-diabetic agents
General laboratory results



















aThe scoring system presents a quantitative severity rating of the most
common adverse effects of immunosuppressive therapy. Each adverse effect
was assessed as a change from pre-transplant status to document that the
manifestation was attributed to immunosuppressive therapy or a change
related therapy in the post-transplant period.
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fects scoring system, nephrologists evaluated individual
stable renal transplant recipients using these pre-
established criteria with documentation of severity (i.e. 0 =
no adverse effect; 1+ =mild to 3+ = severe manifestations).
An overall adverse effect total was determined for each pa-
tient using the sum of individual adverse effect scores. The
cumulative adverse effect ratio was then calculated as the
quotient of each patient’s total score divided by the max-
imum score of all possible manifestations. This cumulative
adverse effect ratio represented the number of adverse ef-
fects with corresponding severity rating. The gastrointes-
tinal, CNS, and aesthetic ratios were generated a posteriori
to further evaluate the organ system specific adverse effects.
For example, if a patient received the following adverse ef-
fect evaluations: vomiting 0, diarrhea 1+, dyspepsia 1+, acid
suppressive therapy 1+, the gastrointestinal adverse effect
ratio would be 3/9 = 0.33 or 33% (9 is maximal possible
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for each ratio provides normalization for the different se-
verity rating among patients to allow comparison.
Statistical analysis
Continuous data was presented as mean± standard deviation
and categorical data as frequency (percentage). Demographic
and clinical parameters were evaluated using student’s T-test
for parametric data, Wilcoxon for non-parametric data, or
Chi-Square for categorical data. All statistical analysis was
performed using SAS version 9.3 (SAS Institute, Cary NC).
Results
A total of 58 stable renal transplant recipients were in-
cluded in this study. Maintenance immunosuppressive reg-
imens consisted of either cyclosporine and MMF (n = 30
males) or tacrolimus plus EC-MPS (n = 28 females and
males). Table 3 provides a comparison of patient demo-
graphics for these two groups.
Content validity was verified by 9 nephrologists out of the
14 requests for completion of the rating survey. The nephrol-
ogists’ survey confirmed that the adverse effects scoring sys-
tem provided moderate-to-significant clinical importance
(3.1 ± 0.75 with maximum score of 4.0) for the assessment of
the 18 adverse effects in renal transplant recipients.
Table 4 provides severity scores and frequencies of indi-
vidual adverse effects for the patients receiving the two
immunosuppressive regimens. Post-transplant diabetes
mellitus was observed in 30.0% of patients receiving cyclo-
sporine and MMF compared to 32.1% of patient receiving
tacrolimus (P = 0.860). Patients treated with tacrolimus
and EC-MPS experienced higher gastrointestinal adverse
effect ratio (0.21 ± 0.15) compared to cyclosporine and
MMF, (0.12 ± 0.11; P = 0.008). Greater CNS adverse effectTable 3 Demographic characteristics
Parametera Cyclosporin
(n =
Age (years) 52.3 ±
Time post-transplant (years) 6.93 ±
Male 30 (10
Caucasian 17 (56
BMI (kg/m2) 33.1 ±
eGFR (ml/min/1.73 m2) 51.7 ±
Albumin 4.24 ±
WBC (cells/mm3) 6.81 ±
MPA dosee 1417 ±
Prednisone use 12 (40
Calcineurin inhibitor trough concentration (ng/ml) 124 ±
aData presented as mean ± standard deviation or frequency (percentage); bT test; c
*p ≤ 0.05: statistical significance.
BMI, body mass index; eGFR, estimated glomerular filtration rate; MMF, mycopheno
sodium; NA, not applicable; WBC, white blood cells.ratio was found in patients treated with tacrolimus and EC-
MPS (0.26 ± 0.18) compared to cyclosporine and MMF (0.16
± 0.17; P = 0.035). There was no difference between patients
treated with tacrolimus and EC-MPS or cyclosporine and
MMF for the cumulative (0.154 ± 0.069 vs. 0.128 ± 0.080;
P = 0.197) or aesthetic (0.101 ± 0.089 vs. 0.133 ± 0.084;
P = 0.161) adverse effect ratios, respectively. For individual ad-
verse effects, 76.7% of patients treated with cyclosporine and
MMF experienced gingival hyperplasia compared to 21.4% of
those treated with tacrolimus and EC-MPS (P < 0.0001). Of
the 316 individual adverse effects scored in all patients, 84.5%
were rated as 1+; 14.9% were rated as 2+; and less than 1%
rated as 3+ (Table 4).
The mean Kappa statistic was 0.68 ± 0.25. The intra-
class correlation was 0.81 (95% confidence interval [CI]:
0.65-0.90) to represent the reliability of summary scores
for the 18 adverse effects. The intra-class correlations for
adverse effect ratios exceeded the a priori designation as
follows: 0.75 (CI: 0.55-0.87) for cumulative; 0.78 (CI: 0.60-
0.88) for gastrointestinal; 0.81 (CI: 0.65-0.90) for CNS; and
0.84 (CI: 0.70-0.92) for aesthetic adverse effect ratios. In-
spection of the Bland-Altman graph (Figure 1) revealed
limited variability between raters without systematic bias.
Discussion
This study presents a novel standardized immunosuppres-
sive adverse effects scoring system for renal transplant
recipients with validation and inter-rater reliability demon-
strated. Multidisciplinary development of this scoring
system with successful application to the intended popula-
tion provides face validity [18]. The heterogeneous nature
of the individual adverse effects depicted in Table 3 empha-
sizes varying degrees of severity and frequency among
stable renal transplant recipients receiving calcineurine + MMF Tacrolimus + EC-MPS P value
30) (n = 28)
9.29 54.1 ± 11.5 0.527b
4.27 5.15 ± 3.34 0.084b
0%) 13 (46.4%) <0.001*
.7%) 13 (46.4%) 0.221c
6.73 30.4 ± 6.94 0.151b
13.5 52.2 ± 18.7 0.921b
0.37 4.26 ± 0.41 0.839b
2.26 6.38 ± 1.52 0.401b
407 1242 ± 319 0.048d*
.0%) 9 (32.1%) 0.585 c
47.1 6.80 ± 1.98 NA
Chi-square test; dWilcoxon test; eExpressed as active mycophenolic acid.
late mofetil; MPA, mycophenolic acid; EC-MPS, enteric coated mycophenolate
Table 4 Frequency of severity scores for immunosuppressive adverse effectsa
Adverse effects 0 1+ 2+ 3+ Overall frequency (as %)
Vomiting 30 / 27 0 / 1 0 / 0 NA 0 / 3.57
Diarrhea 28 / 20 2 / 8 0 / 0 NA 6.67 / 28.6
Dyspepsia 19 / 14 9 / 5 2 / 9 0 / 0 36.7 / 50.0
Acid suppressive therapy 12 / 9 18 / 16 0 / 3 NA 60.0 / 67.9
Acne b 26 / 21 4 / 4 0 / 3 0 / 0 13.3 / 25.0
Skin changes 21 / 21 8 / 5 1 / 2 0 / 0 30.0 / 25.0
Hirsutism 22 / 22 7 / 3 1 / 3 0 / 0 26.7 / 21.4
Moon facies 13 / 17 15 / 11 2 / 0 0 / 0 56.7 / 39.3
Gingival hyperplasia 7 / 22 21 / 6 2 / 0 NA 76.7 / 21.4
Buffalo humpc 21 / 22 9 / 6 NA NA 30.0 / 21.4
Tremor 13 / 7 15 / 16 2 / 4 0 / 1 56.7 / 75.0
Headachec 28 / 22 2 / 6 NA NA 6.67 / 21.4
Insomnia 22 / 15 5 / 9 2 / 4 1 / 0 26.7 / 46.4
Myopathy 27 / 24 2 / 4 1 / 0 0 / 0 10.0 / 14.3
Ophthalmic changesc 17 / 18 13 / 10 NA NA 43.3 / 35.7
Mania 29 / 28 1 / 0 0 / 0 NA 3.33 / 0
Depression 26 / 18 4 / 4 0 / 6 0 / 0 13.3 / 35.7
Post-transplant diabetes mellitusc 21 / 19 9 / 9 NA NA 30.0 / 32.1
Data displayed as cyclosporine and MMF regimen (n = 30) / tacrolimus and EC-MPS regimen (n = 28).
aSeverity score determined using Tables 1 and 2; bNo patients received a 4+ for acne; c rated as present or absent.






























Mean Total Adverse Effect Score
Figure 1 Bland-Altman Plot for Immunosuppressive Adverse Effects Scoring System. This figure presents the inter-rater agreement of n = 32
renal transplant recipients for the adverse effects scoring system with the difference between raters on the y-axis and the mean total adverse effect
score for each patient on the x-axis. Each solid dot represents one patient (Note: there are 7 overlapping data points). The dotted lines represent the
mean difference between the two raters (−0.15; middle line) with the upper and lower bounds of 2 standard deviations around the mean (−3.59, +3.28).
There is little systematic bias or variability between raters.
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sessment of a 3+ score for any adverse effect was less than
1% of all adverse effects during this study since clinically
stable patients were targeted for enrollment. Identifying
transplant patients with mild to moderate adverse effects
may have important clinical impact since drug regimen
adjustments during maintenance immunosuppression may
improve or eliminate these manifestations. Renal transplant
recipients with numerous mild to moderate adverse effects
also have increased risk for medication non-adherence as
time post-transplant increases which may impact long-term
allograft survival [16,17]. Therefore, prospective, standard-
ized monitoring of immunosuppressive adverse effects may
reduce medication non-adherence, improve patient toler-
ability of immunosuppressive regimens and may improve
renal allograft survival [16,17]. In addition, this adverse ef-
fects evaluation system provides an objective approach to
document and rank severity of medication related effects
in patients during clinic visits. Differences in the rating
scales for the individual adverse effects are present (i.e. 0-
2+, 0-3+) based on the smallest detectable incremental
change in manifestation clinically observed by the phys-
ician. This rating is adjusted by using the cumulative and
organ system specific adverse effect ratios which incorpo-
rates internal normalization in order to compare patients.
This approach documents adverse effect frequency and se-
verity which is rarely verified in clinical studies [21].
Nephrologists as subject matter experts verified moder-
ate to significant clinical importance for the individual
adverse effects to be used in the scoring system and sub-
stantiated content validity [18]. Some limitations exist
with this evaluation including physician bias with current
prescribing trends for low glucocorticoid doses or steroid-
free immunosuppressive regimens post-transplant. These
prescribing trends may account for lower clinical importance
scores of steroid associated adverse effects. Since interpatient
variation in clinical response, drug exposure, and adverse ef-
fect manifestations to steroid therapy post-transplant exists,
these adverse effects will remain in the scoring system to
guide maintenance immunosuppression [25-27]. Tailoring
the specific adverse effects scoring system to reflect the inclu-
sion or exclusion of glucocorticoids (i.e. prednisone) in the
immunosuppressive regimen provides a practical and flexible
objective monitoring alternative for transplant recipients.
The adverse effect ratios documented that renal trans-
plant recipients receiving tacrolimus and EC-MPS regi-
men had greater gastrointestinal and CNS adverse effects
compared to patients stabilized on the cyclosporine and
MMF regimen. These findings are consistent with previ-
ous clinical reports [7,22]. Aesthetic adverse effects such
as gingival hyperplasia, hirsutism, acne, and skin changes
are more frequent in cyclosporine treated patients, but
was not observed in this study for the aesthetic adverse
effect ratio [7,21]. This finding may be attributed tosample size or the male predominance in the cyclosporine
group. Additionally, individual aesthetic adverse effects
such as gingival hyperplasia was more frequent in the
cyclosporine treated patients and confirms adverse effect
patterns observed in renal transplant recipients participat-
ing in comparative efficacy studies between these two
immunosuppressive regimens. This finding further verifies
construct validity [19,20,22]. The cumulative adverse
effect ratio was created a priori with incorporation of the
normalization for purpose of interpatient comparison. No
differences were noted in the cumulative ratio between
regimens. However, gastrointestinal, central nervous
system (CNS), and aesthetic adverse effect ratios were
generated a posteriori to further quantitate organ system
specific adverse effects and interpatient differences of these
manifestations were successfully demonstrated. Potential
construct limitations include confounding factors such as
concomitant medications with overlapping adverse effect
profiles and the inability to distinguish causative relation-
ships to individual medications. Since this scoring system
provides a composite of adverse effects manifested by com-
mon immunosuppression regimens, additional factors such
as concomitant medications or co-morbidities should also
be considered during routine clinical assessment.
Inter-rater reliability of the scoring system was substantial
based on intra-class correlation and Kappa analyses
documenting agreement between raters [23,24]. The
overall scoring system and each organ system adverse
effect ratio achieved the a priori endpoint for intra-
class correlation ≥ 0.7. Qualitative assessment of specificity
was observed through rigorous patient assessment meth-
odologies to characterize the adverse effects, the signifi-
cant inter-rater reliability, and calcineurin inhibitor
specific differences in adverse effect profiles observed.
The adverse effects scoring system administered by a
clinician provides a time efficient, standardized clinical
approach to assess the frequency and severity of these
manifestations in renal transplant recipients. In contrast,
the Memphis survey provides a patient completed ques-
tionnaire with comprehensive evaluation of symptoms
and quality of life post-transplant, but does not provide
succinct, efficient, objective adverse effects evaluation
completed by the practitioner [28]. In addition, the pa-
tient completed gastrointestinal symptom rating scale
validated for renal transplant recipients does not include
physician verification or other organ-specific adverse
effects [29]. Therefore, routine clinical application of
these patient rating scales may be limited for objective
immunosuppressive monitoring.
This is a single-center experience in stable renal trans-
plant recipients receiving maintenance immunosuppres-
sion according to pre-established protocols. Therefore,
variability observed in adverse effect manifestations as
detected by the scoring system supports internal validity.
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by participating nephrologists who may provide routine
medical care to some of these patients was possible. Due to
the high inter-rater reliability, this type of bias was mini-
mized. The novelty of the scoring system is the utilization
of clinician directed evaluation of common adverse effects
using a systematic, objective approach instead of a reactive
response to these manifestations. A few infrequent adverse
effects (e.g. alopecia) were not included and may be
considered a study limitation.
Future research using this validated adverse effect rating
system may include longitudinal evaluation of immuno-
suppressive adverse effects during the acute and chronic
post-transplant periods and relationships to medication ad-
herence, physician evaluation and allograft outcomes. This
preliminary report provides a novel standardized adverse
effect assessment which may benefit other solid organ
transplant populations through prospective evaluations.
Conclusions
This validation study presents a clinician administered
immunosuppressive adverse effects scoring system for
stable renal transplant recipients which provides face,
content and construct validity with inter-rater reliability.
The scoring system provides a systematic, standardized,
objective assessment of immunosuppressive adverse
effects that could be utilized for periodic evaluation (i.e.
quarterly) post-transplant to enhance individualization
of immunosuppression. This approach to clinical adverse
effects monitoring may improve patient safety and im-
munosuppressive adherence post-transplant.
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